{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:11:09Z","timestamp":1790464269951,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113481","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T11:59:28Z","timestamp":1730289568000},"page":"113481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"P2","title":["Synergistic Anti-Tumor Effects of Newcastle Disease Virus and Doxorubicin: Evidence from A Murine Breast Cancer Model"],"prefix":"10.1016","volume":"143","author":[{"given":"Hamed","family":"Sabri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5197-1139","authenticated-orcid":false,"given":"Mahdieh Shokrollahi","family":"Barough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Zafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2404-5591","authenticated-orcid":false,"given":"Mahdi","family":"Pakjoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4478-5957","authenticated-orcid":false,"given":"Mehdi","family":"Mahdavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7289-0117","authenticated-orcid":false,"given":"Somaye","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Sarrami-Forooshani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2024.113481_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-022-01012-0","article-title":"Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment","volume":"21","author":"Ghasemi Darestani","year":"2023","journal-title":"Cell Commun. Signal."},{"issue":"12","key":"10.1016\/j.intimp.2024.113481_b0010","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.3390\/v7122921","article-title":"Stem cell-based cell carrier for targeted oncolytic virotherapy: translational opportunity and open questions","volume":"7","author":"Kim","year":"2015","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.intimp.2024.113481_b0015","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113481_b0020","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1586\/14737140.8.10.1581","article-title":"Oncolytic viruses: a novel form of immunotherapy","volume":"8","author":"Prestwich","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"3","key":"10.1016\/j.intimp.2024.113481_b0025","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/biomedicines7030066","article-title":"Breaking therapy resistance: an update on oncolytic newcastle disease virus for improvements of cancer therapy","volume":"7","author":"Schirrmacher","year":"2019","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.intimp.2024.113481_b0030","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41434-020-0145-9","article-title":"Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses","volume":"28","author":"Liu","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.intimp.2024.113481_b0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fonc.2014.00145","article-title":"Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer","volume":"4","author":"Nguyen","year":"2014","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113481_b0040","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3390\/cancers12061699","article-title":"Optimizing oncolytic viral design to enhance antitumor efficacy: progress and challenges","volume":"12","author":"Chaurasiya","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2024.113481_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953410","article-title":"Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements","volume":"13","author":"Yun","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113481_b0050","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.18632\/oncotarget.12284","article-title":"Triple-negative breast cancer: is there a treatment on the horizon?","volume":"8","author":"Yao","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.intimp.2024.113481_b0055","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/1758834017711380","article-title":"Novel therapeutic strategies in the treatment of triple-negative breast cancer","volume":"9","author":"Oualla","year":"2017","journal-title":"Therap. Adv. Med. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113481_b0060","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/vms3.1109","article-title":"Evaluation of the in vitro and in vivo effect of liposomal doxorubicin along with oncolytic Newcastle disease virus on 4T1 cell line: animal preclinical research","volume":"9","author":"Faranoush","year":"2023","journal-title":"Veterinary Med. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2024.113481_b0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.sjbs.2019.04.015","article-title":"Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis","volume":"27","author":"Keshavarz","year":"2020","journal-title":"Saudi J. Biol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2024.113481_b0070","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.113481_b0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/jnci\/djr509","article-title":"Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells","volume":"104","author":"Kanai","year":"2012","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.intimp.2024.113481_b0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"issue":"1","key":"10.1016\/j.intimp.2024.113481_b0085","first-page":"1180","article-title":"Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-\u03b3 and IL-2 from T cells","volume":"16","author":"Zhao","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.intimp.2024.113481_b0090","article-title":"In vitro antigen-specific cytotoxic T cell response against esophageal carcinoma cells induced by HPV18E7-transfected dendritic cells","author":"Wu","year":"2010","journal-title":"Histol. Histopathol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113481_b0095","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.113481_b0100","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/3324247","article-title":"Papaverine enhances the oncolytic effects of newcastle disease virus on breast cancer in vitro and in vivo","volume":"2023","author":"Akram","year":"2023","journal-title":"Int. J. Microbiol."},{"key":"10.1016\/j.intimp.2024.113481_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.845259","article-title":"The combined use of orf virus and PAK4 inhibitor exerts anti-tumor effect in breast cancer","volume":"13","author":"Deng","year":"2022","journal-title":"Front. Microbiol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113481_b0110","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00280-021-04310-5","article-title":"Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression","volume":"88","author":"Sugiu","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113481_b0115","doi-asserted-by":"crossref","first-page":"16843","DOI":"10.1038\/s41598-023-42299-4","article-title":"Combined oncolytic virotherapy gold nanoparticles as synergistic immunotherapy agent in breast cancer control","volume":"13","author":"Jabir","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2024.113481_b0120","unstructured":"M. Naderi, Paclitaxel Enhances Oncolytic Potential of Herpes Simplex Virus Type-1 in Cancer Cells: Louisiana State University and Agricultural & Mechanical College, 2018."},{"issue":"6","key":"10.1016\/j.intimp.2024.113481_b0125","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1128\/JVI.02490-06","article-title":"p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines","volume":"81","author":"F\u00e1bi\u00e1n","year":"2007","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113481_b0130","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2174\/138920112800958850","article-title":"Bugs and drugs: oncolytic virotherapy in combination with chemotherapy","volume":"13","author":"Tusell Wennier","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.intimp.2024.113481_b0135","unstructured":"A. Al-Shammari, N. Yaseen, M. Alwan (Eds.), Cyclophosphamide synergistically enhance Newcastle disease virus Iraqi strain oncolytic activity, in: Poster Presented at: 6th International Conference on Oncolytic Viruses as Cancer Therapeutics, 2011."},{"key":"10.1016\/j.intimp.2024.113481_b0140","doi-asserted-by":"crossref","first-page":"57276","DOI":"10.3389\/fonc.2013.00193","article-title":"Strategies to increase drug penetration in solid tumors","volume":"3","author":"Choi","year":"2013","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113481_b0145","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ijc.29048","article-title":"Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma","volume":"136","author":"Siurala","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2024.113481_b0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/OV.S95250","article-title":"Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy","author":"Al-Shammari","year":"2016","journal-title":"Oncol. Virotherapy"},{"issue":"3","key":"10.1016\/j.intimp.2024.113481_b0155","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3892\/or.2013.2573","article-title":"Induction of apoptosis in MCF-7 cells by the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus Malaysian strain AF2240","volume":"30","author":"Ghrici","year":"2013","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2024.113481_b0160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7599\/hmr.2015.35.2.84","article-title":"Noise-induced hearing loss","volume":"35","author":"Shim","year":"2015","journal-title":"Hanyang Med. Rev."},{"issue":"10","key":"10.1016\/j.intimp.2024.113481_b0165","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/sj.cdd.4401079","article-title":"Decreased glycolytic metabolism contributes to but is not the inducer of apoptosis following IL-3-starvation","volume":"9","author":"Gonin-Giraud","year":"2002","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.intimp.2024.113481_b0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13337-020-00612-z","article-title":"Newcastle disease virus suppress glycolysis pathway and induce breast cancer cells death","volume":"31","author":"Al-Ziaydi","year":"2020","journal-title":"Virusdisease"},{"key":"10.1016\/j.intimp.2024.113481_b0175","first-page":"1","article-title":"Evaluation of D-mannoheptulose and doxorubicin as potential therapeutic agents for breast cancer by targeting glycolysis and inducing apoptosis","author":"Al-Ziaydi","year":"2024","journal-title":"Indian J. Clin. Biochem."},{"key":"10.1016\/j.intimp.2024.113481_b0180","article-title":"Oncolytic effects of Hitchner B1 strain of newcastle disease virus against cervical cancer cell proliferation is mediated by the increased expression of cytochrome C, autophagy and apoptotic pathways","volume":"147","author":"Nejad","year":"2020","journal-title":"Microb. Pathog."},{"issue":"4","key":"10.1016\/j.intimp.2024.113481_b0185","first-page":"363","article-title":"Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation","volume":"6","author":"Datta","year":"1995","journal-title":"Cell Growth Differ."},{"key":"10.1016\/j.intimp.2024.113481_b0190","doi-asserted-by":"crossref","unstructured":"A.J. Minn, C.M. Rudin, L.H. Boise, C.B. Thompson, Expression of bcl-xL can confer a multidrug resistance phenotype, 1995.","DOI":"10.1182\/blood.V86.5.1903.bloodjournal8651903"},{"issue":"6","key":"10.1016\/j.intimp.2024.113481_b0195","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.surg.2003.11.015","article-title":"Prognostic significance of Bcl-xL in human hepatocellular carcinoma","volume":"135","author":"Watanabe","year":"2004","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.intimp.2024.113481_b0200","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1158\/1535-7163.MCT-14-0913","article-title":"Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models","volume":"14","author":"Cuadrado-Castano","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.intimp.2024.113481_b0205","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nrc1750","article-title":"Recent progress in the battle between oncolytic viruses and tumours","volume":"5","author":"Parato","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2024.113481_b0210","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/1097-0142(197412)34:6<1907::AID-CNCR2820340609>3.0.CO;2-4","article-title":"Treatment of human cancer with mumps virus","volume":"34","author":"Asada","year":"1974","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2024.113481_b0215","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/ijc.30811","article-title":"Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus","volume":"141","author":"Jahan","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2024.113481_b0220","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1128\/JVI.01537-10","article-title":"Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells","volume":"85","author":"Mansour","year":"2011","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113481_b0225","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cei.13442","article-title":"Oncolytic adenovirus ORCA-010 increases the type 1 T cell stimulatory capacity of melanoma-conditioned dendritic cells","volume":"201","author":"Lopez Gonzalez","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113481_b0230","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.intimp.2024.113481_b0235","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ijc.32694","article-title":"Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo","volume":"146","author":"Xu","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2024.113481_b0240","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.4049\/jimmunol.164.4.1753","article-title":"Measles virus induces abnormal differentiation of CD40 ligand-activated human dendritic cells","volume":"164","author":"Servet-Delprat","year":"2000","journal-title":"J. Immunol."},{"issue":"13","key":"10.1016\/j.intimp.2024.113481_b0245","doi-asserted-by":"crossref","first-page":"5958","DOI":"10.1128\/JVI.75.13.5958-5964.2001","article-title":"Immature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1","volume":"75","author":"Mikloska","year":"2001","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113481_b0250","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1038\/s41467-022-34791-8","article-title":"Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity","volume":"13","author":"Svensson-Arvelund","year":"2022","journal-title":"Nat. Commun."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924020034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924020034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:34:09Z","timestamp":1736303649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924020034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":50,"alternative-id":["S1567576924020034"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113481","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic Anti-Tumor Effects of Newcastle Disease Virus and Doxorubicin: Evidence from A Murine Breast Cancer Model","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113481"}}